TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6448025
Drug: Vehicle alone
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle alone applied twice daily for eight weeks
Study: 6448025
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin hydrochloride hydrate
Study: 28261906
Drug: Two-piece implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece implant with a progressive platform widening and a platform switching connection (SP)
Study: 28261906
Drug: One-piece implant
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece implant with a machined collar (TG)
Study: 19752419
Drug: 1‐mg intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg intravitreal triamcinolone
Study: 19752419
Drug: 4‐mg intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mg intravitreal triamcinolone
Study: 19752419
Drug: 1‐mg vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg vs 4‐mg intravitreal triamcinolone
Study: 19752419
Drug: Observation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation and 1‐mg intravitreal triamcinolone
Study: 15537905
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of anti-interleukin-12 per kilogram
Study: 7826790
Drug: Midwife top‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife top‐up doses of 0.25% bupivacaine 10 ml
Study: 7826790
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% bupivacaine 10 ml h‐1
Study: 7826790
Drug: Patient-controlled extradural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled extradural analgesia (PCEA) with self‐administered 3‐ml bolus doses of 0.25% bupivacaine
Study: 29798443
Drug: Ginkgo Leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Leaves Soft-gel Capsule and Qiangli Dingxuan tablets (Drug group)
Study: 22298804
Drug: Cotreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotreatment with pegvisomant (15‐30 mg twice a week) and SA (half the usual dosage)
Study: 22298804
Drug: SA monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA monotherapy
Study: 19356426
Drug: Systematic heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic heart rate control (oral and intravenous beta-blockade for a target heart rate ≤60 beats/min) in single-source CT
Study: 15161787
Drug: metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (1,500 mg/day)
Study: 11578882
Drug: Fentanyl (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (administered according to anesthesiologists' usual practice)
Study: 7816293
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.1 ml of the vehicle
Study: 7816293
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.33 ml of the vehicle
Study: 18652318
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese drug Tongru Decoction
Study: 10877171
Drug: ICD p24
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICD p24 antigen with p24 antibody
Study: 9096815
Drug: 1.23 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23 percent acidulated phosphofluoride conventional gel
Study: 9096815
Drug: 1.23 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23 percent acidulated phosphofluoride thixotropic gel
Study: 9096815
Drug: 2 percent
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GEL [The Keeps ETHANOL 62 percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 percent neutral sodium fluoride solution
Study: 8414860
Drug: Topical 30%
Normalized name: urea topical 30% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 30% lidocaine cream
Study: 8414860
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base alone (placebo)
Study: 3469166
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline daily for ten days
Study: 3469166
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ofloxacin twice a day for nine days
Study: 29072027
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with analgesics and physical therapy
Study: 23020674
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 1 ng.ml(‐1)
Study: 23020674
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 3 ng.ml(‐1)
Study: 23020674
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration of 5 ng.ml(‐1)
Study: 17630038
Drug: Torcetrapib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib (60 mg per day) with atorvastatin
Study: 17630038
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone (placebo group)
Study: 9348568
Drug: Leucovorin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin plus fluorouracil (5‐FU) 425 mg/m2, days 1 through 5, 28‐day cycle
Study: 9348568
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin plus oral UFT (tegafur and uracil) 300 mg/m2, days 1 through 28, 35‐day cycle
Study: 2939868
Drug: Doxazosin 1-16
Normalized name: doxazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1-16 mg day-1 (mean daily dose 11.8 mg)
Study: 2939868
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg day-1 (mean daily dose 94.2 mg)
Study: 28410406
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 μg/day for 28 days)
Study: 26284719
Drug: Tinzaparin (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (175 IU/kg) once daily for 6 months
Study: 26284719
Drug: Warfarin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (after 5 to 10 days of tinzaparin) adjusted to maintain INR 2.0-3.0 for 6 months
Study: 23983064
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily pregabalin (300 mg daily)
Study: 23983064
Drug: Once nightly
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once nightly pregabalin (300 mg daily)
Study: 23983064
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily pregabalin
Study: 17540667
Drug: Aprepitant 40
Normalized name: aprepitant 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 40 mg and 125 mg
Study: 10724076
Drug: Thrice-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly resistance training and twice-weekly endurance training for 4 to 8 weeks
Study: 9201083
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (360 ml) during meals
Study: 1447392
Drug: Metronidazole 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 25% dental gel applied subgingivally (2 applications on days 0 and 7)
Study: 31371287
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid supplementation and in-bed cycle ergometry exercise
Study: 24595047
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (ART commenced at mean age of 8 weeks)
Study: 24595047
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (ART commenced at mean age of 18.5 weeks)
Study: 23921822
Drug: Lignocaine hydrochloride
Normalized name: Lignocaine hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine hydrochloride 10 mg
Study: 16368305
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/d) for 3 months
Study: 8973228
Drug: Anticoagulation (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant)
Study: 15337874
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg daily)
Study: 1330848
Drug: high-dose immunoglobulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose immunoglobulins (h.d. Ig)
Study: 31506094
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product containing moxidectin (24-48 µg/kg), sarolaner (2-4 mg/kg), and pyrantel (5-10 mg/kg)
Study: 31506094
Drug: Moxidectin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin alone (24 µg/kg)
Study: 31506094
Drug: Sarolaner alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner alone (2 mg/kg)
Study: 31506094
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product (moxidectin, sarolaner, pyrantel)
Study: 18041415
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar (10% LCD) cream
Study: 18041415
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate cream (0.1%)
Study: 15604515
Drug: APOA5 polymorphisms
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APOA5 polymorphisms 27376 and 28837 (‐3A/G)
Study: 11850305
Drug: Nurse‐directed, multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse‐directed, multidisciplinary intervention (including education of patient and family, social support, review of medication, dietary modification and weight monitoring)
Study: 7562170
Drug: Dental implant‐retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant‐retained overdentures
Study: 7562170
Drug: Overdentures retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overdentures retained by dental implants
Study: 2338386
Drug: Indomethacin 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.5% ophthalmic suspension
Study: 373988
Drug: Co-trimoxazole (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (480 mg trimethoprim and 2400 mg sulphamethoxazole) per day
Study: 373988
Drug: Tetracycline 2
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 2 g per day
Study: 29113874
Drug: pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (5 mg, p.o.)
Study: 25751701
Drug: Stepped-care intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care intervention (12 weeks of analgesic treatment and optimization, followed by 12 weeks of cognitive behavioral therapy)
Study: 23808902
Drug: 3-year adjuvant
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-year adjuvant imatinib therapy
Study: 23808902
Drug: 1-year adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year adjuvant imatinib therapy
Study: 3318375
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem (329 mg daily)
Study: 3318375
Drug: Atenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (80 mg daily)
Study: 27744447
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CT + Paroxetine)
Study: 24937025
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (400-4,800 IU/d) with calcium intake of approximately 1,200 mg/day
Study: 23480554
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin (0.5 mg + 0.02 mg/kg/d)
Study: 18346293
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg memantine for 12 weeks
Study: 1782932
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (TNG) patch (10 mg.24 h‐1) with a daily overnight 8‐h free interval
Study: 30406392
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg thrice/day for 2 weeks)
Study: 27740850
Drug: No lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lotion
Study: 24263176
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg twice daily for 28 days
Study: 24263176
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg twice daily for 28 days (excluding minimal to no baseline aggression)
Study: 23449748
Drug: Astaxanthin 4-mg
Normalized name: astaxanthin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 4-mg capsules + splinting
Study: 18395477
Drug: Atorvastatin (10mg-80mg)
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (10mg-80mg) for 6 months
Study: 15359265
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac (0.5%)
Study: 10933357
Drug: Bladder distention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder distention in group 2 (pretreatment with doxazosin, 2 mg)
Study: 10933357
Drug: Nitroglycerin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin administration after bladder distention
Study: 8661952
Drug: AAA Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAA Ca (900 mg/day)
Study: 8661952
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (900 mg/day)
Study: 1645104
Drug: 0.32 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32 mg/70 kg triazolam
Study: 1645104
Drug: Placebo (lactose-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose-filled capsules)
Study: 6387488
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of an agonist of gonadotropin‐releasing hormone
Study: 30715168
Drug: pemetrexed and
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed and a platinum-based chemotherapy (cisplatin or carboplatin) plus 200 mg of pembrolizumab every 3 weeks for 4 cycles, followed by pembrolizumab for up to a total of 35 cycles plus pemetrexed maintenance therapy
Study: 22068424
Drug: Easy Vax™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easy Vax™ dermal electroporation system (administered in two areas, total of six doses)
Study: 22068424
Drug: Easy Vax™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easy Vax™ dermal electroporation system (administered in deltoid regions only after initial complaints)
Study: 21118176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy for EVI treatment of IHD)
Study: 18509971
Drug: Treatment 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1: Oral MgSO4 solution before operation, Cefradine 2.0 g (I.V.) during anesthesia induction, followed by two doses of Cefradine 2.0 g and 0.5% Metronidazole 100 ml at 12-hour intervals for 24 hours post-operation.
Study: 18509971
Drug: Treatment 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2: Same as Treatment 1, but antibiotics continued for 3-5 days post-operation.
Study: 18509971
Drug: Control: Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Oral antibiotics 2-3 days before operation.
Study: 10588553
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection (group 2)
Study: 10588553
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (group 1)
Study: 1873582
Drug: Stomatognathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stomatognathic treatment and biofeedback therapy
Study: 31842784
Drug: Robotic-assisted/standard laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted/standard laparoscopic rectal cancer surgery after 8 weeks
Study: 31842784
Drug: Robotic-assisted/standard laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted/standard laparoscopic rectal cancer surgery after 12 weeks
Study: 24585721
Drug: TAC +
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC + zoledronic acid (ZA) 4 mg i.v. every 3 weeks
Study: 17426604
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) (N=10)
Study: 17426604
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) (N=12)
Study: 11287020
Drug: 0.0625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625 mg/d GnRH antagonist
Study: 11287020
Drug: 0.125 mg/d
Normalized name: fluoride 0.125 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/d GnRH antagonist
Study: 11287020
Drug: 0.25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/d GnRH antagonist
Study: 11287020
Drug: 0.5 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/d GnRH antagonist
Study: 11287020
Drug: 1.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/d GnRH antagonist
Study: 11287020
Drug: 2.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/d GnRH antagonist
Study: 11287020
Drug: Increasing GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing GnRH antagonist doses
Study: 9103484
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (group 2, n = 6) injected into gluteal muscle in 4 ml of arachis oil
Study: 9103484
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (group 3, n = 5) in 1 ml of arachis oil injected into gluteal muscle
Study: 9103484
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (group 4, n = 5) in 1 ml of arachis oil injected into deltoid muscle
Study: 9103484
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 1-ml gluteal injection
Study: 3733274
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g i.v.) with frusemide (40 mg p.o.)
Study: 3733274
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g i.v.) with placebo
Study: 28417592
Drug: Allopurinol (50-700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50-700 mg daily)
Study: 28417592
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on allopurinol dose-response relationship
Study: 25176167
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus psychotherapy treatment for the depressed cohort
Study: 21885884
Drug: Daily weather
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily weather conditions (temperature, rainfall, snowfall, daylight hours)
Study: 16705847
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus point-injection at points Quchi (LI11), Xuehai (SP10), Zusanli (ST36), Sanyinjiao (SP6), and Fengchi (GB20) plus point-injection at Zusanli (ST36) and Quchi (LI11)
Study: 16705847
Drug: Antihistamines (Acrivastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (Acrivastine, Cinnarizine, Ranitidine)
Study: 15346264
Drug: Thalidomide monotherapy
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide monotherapy (n = 38)
Study: 15346264
Drug: Thalidomide combined
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide combined with chemotherapy (n = 25)
Study: 11602481
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment (shocks of 0 mJ/mm(2) energy)
Study: 9810943
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine injections
Study: 9810943
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine infusions
Study: 9810943
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine injections and infusions
Study: 8206677
Drug: Pre-treatment sTNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment sTNF-alpha R concentration
Study: 27725164
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for 7 days
Study: 26342236
Drug: Molecularly targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly targeted agents (experimental group)
Study: 26342236
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at physician's choice (control group)
Study: 26342236
Drug: Cytotoxic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy (control group)
Study: 21632605
Drug: Small priming
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small priming dose of etomidate (0.03 mg kg(‐1))